NEW YORK, August 5, 2015 /PRNewswire/ --
ACI Association has initiated research coverage on Aquinox Pharmaceuticals Inc. (NASDAQ: AQXP). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.
Today, membership is open to readers on a complementary basis at the following URL: http://www.aciassociation.com/?c=AQXP
Highlights from our AQXP Report include:
- Results from the FLAGSHIP Trial - On July 09, 2015, Aquinox Pharmaceuticals Inc. (Aquinox) announced that its Phase 2 FLAGSHIP clinical trial failed to demonstrate efficacy in chronic obstructive pulmonary disease (COPD) patients with a history of frequent exacerbations. The Company said that the patients, who were given an oral dose of 200 mg AQX-1125 for 12 weeks on a daily basis, demonstrated no difference in COPD symptoms compared to placebo, as measured by a patient-reported outcome tool called EXACT. Moreover, no benefits were observed with AQX-1125, on the secondary endpoint of medically treated exacerbations. Though consistent with past results, the FLAGSHIP trial with AQX-1125 was well tolerated, the overall adverse event rate was similar between AQX-1125 and placebo.
- Management Comments - President & CEO at Aquinox, David Main said, "We believe that FLAGSHIP was a robust and well conducted trial and the results are conclusive." He added, "Given the encouraging activity seen in our recent LEADERSHIP trial our focus will be on the further development of AQX-1125 in bladder pain syndrome/interstitial cystitis. In addition, we are awaiting results from our KINSHIP trial in atopic dermatitis."
- An overview of the FLAGSHIP trial - While elaborating on the details of the FLAGSHIP trial, Aquinox said that this multicenter, randomized (1:1), double-blind, placebo-controlled, Phase 2 clinical trial was initiated in July 2013. It was conducted to examine the ability of 200mg AQX-1125 oral dose of AQX-1125 in reducing the effects of exacerbations in patients with moderate to severe COPD. The primary endpoint of the study was the change in the severity, duration and recurrence of COPD exacerbations in patients treated with AQX-1125 versus placebo, as measured by EXACT.
- Aquinox's lead drug candidate - AQX-1125 - Aquinox's drug candidate, AQX-1125 is a small molecule activator of SHIP1, a regulating component of the PI3K cellular signaling pathway. AQX-1125 increases SHIP1 activity and accelerates a natural mechanism that has evolved to maintain homeostasis of the immune system and to reduce immune cell activation and migration to sites of inflammation. In various preclinical studies and clinical trials conducted by the Company, AQX-1125 demonstrated preliminary safety and favorable drug properties. Additionally, the Company is also examining AQX-1125 for atopic dermatitis in its ongoing KINSHIP Phase 2 trial and its top-line data is scheduled for release by the first quarter of 2016.
To find out how this influences our rating on Aquinox Pharmaceuticals Inc., read the full report in its entirety here: http://www.aciassociation.com/?c=AQXP
About ACI Association:
Active Charter Investors Association ("ACI Association") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ACI Association has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
ACI Association has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the CFA® have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the CFA® (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.
ACI Association, the Author, the Reviewer and the CFA® (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ACI Association nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.aciassociation.com/.
ACI Association is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at) aciassociation.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.